Neurochromatic trial lens kit

ABSTRACT

A trial lens kit for determining a neurochromatic lens prescription for the eye. The trial lens kit includes a first plurality of trial lenses wherein each of the first plurality of trial lenses is operable to filter a particular wavelength of light. The first plurality of trial lenses corresponds to a first type of visual function improvement. The trial lens kit further comprises a second plurality of trial lenses where each of the second plurality of trial lenses is operable to filter a particular wavelength of light. The second plurality of trial lenses corresponds to a second type of visual function improvement. The first plurality of trial lenses and the second plurality of trial lenses are operable for determining a neurochromatic prescription.

RELATED U.S. APPLICATIONS

This application claims the benefit of and priority to the copendingprovisional patent application Ser. No. 61/470,417, Attorney DocketNumber NCVS-0001.A, entitled “SYSTEMS AND METHODS FOR CHROMATIC VISIONENHANCEMENT,” with filing date Mar. 31, 2011, and hereby incorporated byreference in its entirety.

This application is related to copending non-provisional patentapplication, Serial Number 13/368,149, Attorney Docket NumberNCVS-0001.US1, entitled “NEUROCHROMATIC PRESCRIPTION DETERMINATION,”with filing date 2/7/12, and hereby incorporated by reference in itsentirety.

This application is related to copending non-provisional patentapplication Ser. No. ______, Attorney Docket Number NCVS-0001.US3,entitled “NEUROCHROMATIC REFRACTOR,” with filing date ______, and herebyincorporated by reference in its entirety.

This application is related to copending non-provisional patentapplication Ser. No ______, Attorney Docket Number NCVS-0001.US4,entitled “NEUROCHROMATIC PRESCRIPTION DETERMINATION,” with filing date______, and hereby incorporated by reference in its entirety.

FIELD OF THE INVENTION

Embodiments of the present invention are generally related to visionenhancement, e.g., with the application of specialized and custom lensesfor the eyes.

BACKGROUND OF THE INVENTION

Vision is one of the most important senses. People are in particularheavily visual in nature, often favoring visual perception over othersenses. Further, humans constantly use their eyes in almost every taskwhether it be for reading, walking, or driving. This reliance on thevisual system as the primary sense for interacting with the world makesthe human eye incredibly important and thereby meaning any deficiency invisual performance can have a large negative impact on health andperception.

The eye and the visual processing system are quite complex and as suchcan be negatively impacted by a variety of conditions, syndromes, andcomplications. Such problems can result in photophobia, reduced field ofvision, clarity of vision, and other visual compromises. Whileophthalmic prescriptions are somewhat effective in reducing the negativeeffects of near-sightedness and far-sightedness, ophthalmicprescriptions and lenses are not able to solve or reduce a variety ofconditions, syndromes, and complications. For example, ophthalmic lenseshave limited effect on photophobia or reduced field of vision. Regulareye glasses mostly correct for image clarity and focus but do little tocorrect for other visual performance and acuity issues.

Thus, a need exists for a solution to alleviate visual system problemsthat are not solved or fully solved with current ophthalmicprescriptions and lenses.

SUMMARY OF THE INVENTION

Embodiments of the present invention are operable for use in determininga neurochromatic prescription to medically and therapeutically treat orenhance the performance of the human visual experience by physicianprescribed neurochromatic lenses. Embodiments of the present inventioninclude a plurality of trial lenses for determining effective treatmentfor the enhancement of vision and therapeutic treatment for a variety ofneurovisual processing symptoms, anomalies, conditions, and syndromes.

Embodiments of the present invention are operable to improve a varietyof various visual performance and visual function characteristicsincluding improved visual acuity (e.g., more clear and enhanced visualperception of distant objects), improved visual field, enhanced visualsaccade (e.g., eye movement across a page), increased contrastsensitivity, and increased recognition of color hues. Embodiments of thepresent invention are further operable to improve visual performance andvisual function characteristics including increased eye coordination,increased pupil stabilization (e.g., stabilization of pupil shape toround), improved visual invoked response time (e.g., vision to actiontime), and improved blood flow in the brain which results in enhancementto cognitive response to visual cues. Embodiments of the presentinvention may include such Neurochromatic™ lenses or trial lensesavailable from NeuChroma Vision, Incorporated of Redding, Calif.

In one embodiment, the present invention is a trial lens kit operable tobe used by a technician or medical agent for determining aneurochromatic lens prescription for the eye. The trial lens kitincludes a first plurality of trial lenses wherein each of the firstplurality of trial lenses is operable to filter a particular wavelengthof light. The first plurality of trial lenses corresponds to a firsttype of visual function improvement. The first plurality of trial lensesmay comprise an ordered arrangement of colored trial lenses (e.g., madeof tinted plastic). The trial lens kit further comprises a secondplurality of trial lenses where each of the second plurality of triallenses is operable to filter a particular wavelength of light. Thesecond plurality of trial lenses may be in an ordered arrangement andcorresponds to a second type of visual function improvement. In oneembodiment, the second plurality of lenses may comprise infrared (IR)trial lenses operable to filter IR wavelengths. The first plurality oftrial lenses and the second plurality of trial lenses are operable to becombined for determining a neurochromatic prescription as a result ofvisual sampling with the patient. The first type of visual functionimprovement and the second type of visual function improvement may berelated to a first pupillary anomaly and a second pupillary anomalyrespectively. The trial lens kit may further comprise a third pluralityof trial lenses where each of the third plurality of trial lenses may bein an ordered arrangement and is operable to filter ultraviolet (UV)light. The third plurality of trial lenses may correspond to a thirdtype of visual function improvement and may be combined with otherselected lenses.

In one embodiment, the present invention is an apparatus fordetermination of a chromatic prescription. The apparatus comprises afirst trial lens operable to filter a first portion of theelectromagnetic spectrum and corresponding to a first type of visualfunction improvement related to a first pupillary anomaly. The apparatusfurther includes a second trial lens operable to filter a second portionof the electromagnetic spectrum and corresponding to a second type ofvisual function improvement related to a second pupillary anomaly. Thefirst trial lens and the second trial lens are operable in combinationto correspond to a third visual function improvement. In one embodiment,the first trial lens may correspond to a first tint of a color and thesecond trial lens corresponds to a second tint of the color. The colormay be selected from the group consisting of red, orange, yellow, green,blue, indigo, and violet. The first trial lens and the second trial lensmay be tinted via a dyeing process. In one embodiment, the first triallens corresponds to a first ultraviolet (UV) wavelength and the secondtrial lens corresponds to a second ultraviolet wavelength. In anotherembodiment, the first trial lens corresponds to a first infrared (IR)wavelength and the second trial lens corresponds to a second infraredwavelength. The first trial lens and second trial lens may be made ofplastic and made substantially accordingly to ophthalmic standards.

In another embodiment, the present invention is as a lens kit. The lenskit includes a plurality of color trial lenses corresponding to a firstvisual function improvement and a plurality of ultraviolet (UV) triallenses corresponding to a second visual function improvement. Theplurality of color trial lenses may be made of tinted plastic (e.g.,tinted using a dyeing process). The lens kit further includes aplurality of infrared (IR) trial lenses corresponding to a third visualfunction improvement. The plurality of color trial lenses, the pluralityof UV trial lenses, and the plurality of IR trial lenses are operablefor determination of a chromatic prescription. The first visual functionimprovement and the second visual function improvement may be related toa first pupillary anomaly and a second pupillary anomaly respectively.In one embodiment, the lens kit further comprises a plurality of neutraldensity trial lenses corresponding to a fourth visual functionimprovement. In another embodiment, the lens kit comprises a pluralityof plated lenses corresponding to a fifth visual function improvement.

BRIEF DESCRIPTION OF THE DRAWINGS

The present invention is illustrated by way of example, and not by wayof limitation, in the figures of the accompanying drawings and in whichlike reference numerals refer to similar elements.

FIG. 1 shows a block diagram of an exemplary trial lens kit inaccordance with an embodiment of the present invention.

FIG. 2 shows a block diagram of an exemplary trial lens in accordancewith an embodiment of the present invention.

FIG. 3 shows a block diagram of an exemplary case in accordance with anembodiment of the present invention.

DETAILED DESCRIPTION OF THE INVENTION

Reference will now be made in detail to the preferred embodiments of thepresent invention, examples of which are illustrated in the accompanyingdrawings. While the invention will be described in conjunction with thepreferred embodiments, it will be understood that they are not intendedto limit the invention to these embodiments. On the contrary, theinvention is intended to cover alternatives, modifications andequivalents, which may be included within the spirit and scope of theinvention as defined by the appended claims. Furthermore, in thefollowing detailed description of embodiments of the present invention,numerous specific details are set forth in order to provide a thoroughunderstanding of the present invention. However, it will be recognizedby one of ordinary skill in the art that the present invention may bepracticed without these specific details. In other instances, well-knownmethods, procedures, components, and circuits have not been described indetail as not to unnecessarily obscure aspects of the embodiments of thepresent invention.

Exemplary Neurochromatic Trial Lens Kit

FIG. 1 shows a block diagram of an exemplary trial lens kit inaccordance with an embodiment of the present invention. Exemplary triallens kit 100 includes trial lenses 120-174. FIG. 1 depicts an exemplarygrouping or ordered arrangement according to characteristics of eachlens of trial lens kit 100. Each trial lens of trial lens kit 100 mayfilter a specific frequency or wavelength or portion of theelectromagnetic spectrum or electromagnetic radiation (e.g., visiblelight, infrared, ultraviolet, etc.). Each trial lens of trial lens kitmay be related to a visual function improvement of a particularpathology or pupillary anomaly. In one embodiment, trial lens kit 100includes 100 lenses. It is appreciated that trial lens kit 100 can haveany number of lenses.

In one exemplary embodiment, exemplary trial lens kit 100 includesgroups 102-110. It is noted that groups 102-110 are exemplary and thatexemplary trial lens kit 100 may comprise more or less groups andembodiments of the present invention are not limited to groupings ofgroups 102-110. It is further noted the groups 102-110 may comprisesmore or less trial lens than shown in FIG. 1 and are not limited to thenumber of lenses corresponding to groups 102-110. Each of groups 102-110may comprise similar properties associated with treating one or morepathologies or pupillary anomalies.

In one embodiment, trial lens kit 100 is operable for determining achromatic or neurochromatic prescription as described in relatedcopending non-provisional patent application Ser. No. 13/368,149,Attorney Docket Number NCVS-0001.US1, entitled “NEUROCHROMATICPRESCRIPTION DETERMINATION,” with filing date Feb. 7, 2012, and herebyincorporated by reference in its entirety.

In one embodiment, trial lens kit 100 and corresponding groups 102-110are arranged so that a physician may move sequentially through thelenses of lens kit 100 providing visual samples to a patient todetermine a neurochromatic prescription. In one exemplary embodiment,trial lens kit 100 is setup to test plated lenses, infrared (IR) lenses,neutral density lenses, color trial lenses, and then ultraviolet (UV)trial lenses. One or more lenses from each of groups 102-110 may becombined to arrive at a chromatic prescription and thus a prescriptivelens. In one embodiment, trial lens kit 100 comprises a platedlenses/coded lenses group which includes lenses that are coated (e.g.,reflectively coated and/or having a slight curvature). The plated lensesgroup may include lenses available from Mar-Lite Optical Suppliers ofModesto, Calif.

Exemplary groupings of trial lens kit 100 operable for determining aneurochromatic prescription for enhancing visual performance and/orproviding neurovisual therapeutic intervention therapy for the symptoms,syndromes, conditions, and anomalies is shown within Table I. It isappreciated that trial lens kit 100 may have different groupings thanthose shown in Table I. In one embodiment, trial lens kit 100 isarranged such that a physician can step through lens kits in the ordershown in Table I (e.g., starting with UV trial lenses in the bottom leftfront corner of trial lens kit 100 and continuing up over, down, and upthrough lens kit 100). Exemplary spectrometry readings and correspondinginformation of exemplary trial lens kit 100, in accordance with oneembodiment, are shown below in Appendix A.

TABLE I Exemplary Trial Lens Kit Groupings and Characteristics VisibleLight Red Green Yellow Blue UV Group/ Transmitted TransmittedTransmitted Transmitted Transmitted Transmitted Lens (%) (%) (%) (%) (%)(%) 1 Ultraviolet (UV) Group UV Lens 95.9% 96.7% 95.6% 96.4% 95.3% 0.1%#1 (UV1) UV Lens 95.4% 96.2% 95.2% 95.9% 94.9% 0.0% #2 (UV2) UV Lens95.7% 96.5% 95.5% 96.2% 95.1% 0.0% #3 (UV3) 2 Neutral Density Group:Reduces Spectrum (e.g., removing glare and providing darkness) Neutral83.5% 84.7% 83.5% 83.7% 84.2% 2.1% Density Lens #1 (ND1) Neutral 83.5%84.7% 83.5% 83.7% 84.2% 2.1% Density Lens #1 (ND1) Neutral 62.2% 63.2%63.3% 62.0% 65.3% 1.2% Density Lens #2 (ND2) Neutral 44.2% 46.6% 44.5%44.2% 47.3% 0.4% Density Lens #3 (ND3) 3 Infrared (IR) Lens Group IRLens #1 81.2% 83.1% 81.0% 81.9% 81.5% 2.1% (IR1) IR Lens #1 81.2% 83.1%81.0% 81.9% 81.5% 2.1% (IR1) IR Lens #2 80.3% 84.9% 78.7% 82.8% 78.4%1.8% (IR2) IR Lens #3 34.6% 45.8% 30.8% 40.4% 30.8% 0.0% (IR3) IR Lens#4 32.2% 42.0% 29.2% 36.8% 30.5% 0.0% (IR4) 4 Colored Lens Group Brown#1 86.0% 89.7% 84.5% 88.2% 83.8% 2.1% (BR1) Brown #1 86.0% 89.7% 84.5%88.2% 83.8% 2.1% (BR1) Brown #2 74.6% 81.5% 71.9% 78.6% 70.9% 1.4% (BR2)Brown #3 62.6% 72.6% 58.8% 68.4% 57.6% 0.6% (BR3) Orange #1 89.7% 93.2%88.5% 91.7% 87.8% 2.3% (OR1) Orange #1 89.7% 93.2% 88.5% 91.7% 87.8%2.3% (OR1) Orange #2 81.3% 89.7% 78.2% 85.7% 77.9% 1.6% (OR2) Orange #369.3% 87.5% 62.9% 78.6% 62.1% 0.3% (OR3) Amber #1 89.7% 92.9% 88.6%91.7% 87.3% 1.8% (AM1) Amber #1 89.7% 92.9% 88.6% 91.7% 87.3% 1.8% (AM1)Amber #2 82.9% 88.9% 80.9% 86.5% 79.2% 1.1% (AM2) Amber #3 75.5% 84.4%72.6% 80.8% 70.0% 0.3% (AM3) Yellow #1 96.6% 97.8% 96.3% 97.4% 95.4%2.4% (YL1) Yellow #1 96.6% 97.8% 96.3% 97.4% 95.4% 2.4% (YL1) Yellow #296.3% 97.9% 95.9% 97.5% 94.2% 1.9% (YL2) Yellow #3 94.7% 97.6% 94.1%97.0% 90.2% 0.7% (YL3) Green #1 92.3% 92.1% 92.7% 92.1% 92.4% 2.3% (GR1)Green #1 92.3% 92.1% 92.7% 92.1% 92.4% 2.3% (GR1) Green #2 78.0% 75.2%80.2% 76.1% 79.6% 0.6% (GR2) Green #3 61.9% 55.9% 65.7% 58.3% 64.7% 0.0%(GR3) Moss 84.3% 84.6% 84.7% 84.3% 84.5% 1.6% Green #1 (MS1) Moss 84.3%84.6% 84.7% 84.3% 84.5% 1.6% Green #1 (MS1) Moss 76.0% 76.0% 76.8% 75.5%77.2% 1.4% Green #2 (MS2) Moss 60.3% 59.4% 61.8% 59.1% 62.4% 0.2% Green#3 (MS3) Pink #1 92.4% 97.1% 90.6% 94.6% 91.0% 2.8% (PK1) Pink #1 92.4%97.1% 90.6% 94.6% 91.0% 2.8% (PK1) Pink #2 87.5% 96.5% 84.1% 91.7% 85.3%2.7% (PK2) Pink #3 78.4% 95.0% 72.2% 86.1% 74.7% 2.7% (PK3) Red #1 88.4%92.8% 86.8% 90.6% 86.9% 2.7% (RD1) Red #1 88.4% 92.8% 86.8% 90.6% 86.9%2.7% (RD1) Red #2 83.4% 90.5% 80.7% 86.9% 81.1% 2.2% (RD2) Red #3 60.5%85.2% 51.6% 72.2% 53.5% 0.8% (RD3) Burgundy 70.6% 84.0% 65.7% 77.0%67.5% 2.1% #1 (BG1) Burgundy 70.6% 84.0% 65.7% 77.0% 67.5% 2.1% #1 (BG1)Burgundy 67.4% 81.6% 62.2% 74.0% 64.5% 2.1% #2 (BG2) Burgundy 59.4%79.3% 52.0% 68.8% 54.5% 1.2% #3 (BG3) Rosewood 75.6% 88.1% 70.9% 81.9%71.8% 2.2% #1 (RW1) Rosewood 75.6% 88.1% 70.9% 81.9% 71.8% 2.2% #1 (RW1)Rosewood 74.6% 85.6% 70.5% 80.3% 70.7% 1.7% #2 (RW2) Rosewood 63.2%80.2% 56.8% 71.8% 57.7% 1.0% #3 (RW3) Lavender 81.7% 84.2% 80.9% 82.5%82.5% 2.4% #1 (LV1) Lavender 81.7% 84.2% 80.9% 82.5% 82.5% 2.4% #1 (LV1)Lavender 76.3% 79.1% 75.5% 76.9% 78.1% 2.7% #2 (LV2) Lavender 66.1%71.1% 64.5% 67.6% 68.1% 2.5% #3 (LV3) Violet #1 80.1% 84.5% 79.4% 80.6%82.5% 2.7% (VL1) Violet #1 80.1% 84.5% 79.4% 80.6% 82.5% 2.7% (VL1)Violet #2 77.3% 82.1% 76.7% 77.8% 80.4% 3.0% (VL2) Violet #3 69.5% 76.0%68.7% 69.9% 74.2% 2.6% (VL3) Royal 81.8% 81.2% 82.5% 80.7% 84.0% 2.8%Blue #1 (RB1) Royal 81.8% 81.2% 82.5% 80.7% 84.0% 2.8% Blue #1 (RB1)Royal 67.3% 66.3% 68.9% 65.2% 72.0% 2.1% Blue #2 (RB2) Royal 43.3% 41.9%45.6% 40.1% 50.8% 1.0% Blue #3 (RB3) Blue #1 91.2% 89.2% 92.3% 89.8%93.0% 2.7% (BL1) Blue #1 91.2% 89.2% 92.3% 89.8% 93.0% 2.7% (BL1) Blue#2 88.7% 85.3% 90.4% 86.3% 91.6% 2.6% (BL2) Blue #3 81.8% 75.2% 85.2%77.2% 87.7% 2.7% (BL3) Sky Blue 90.3% 88.1% 91.3% 89.0% 91.5% 2.4% #1(SK1) Sky Blue 90.3% 88.1% 91.3% 89.0% 91.5% 2.4% #1 (SK1) Sky Blue85.6% 81.5% 87.5% 83.1% 88.3% 2.3% #2 (SK2) Sky Blue 80.1% 73.2% 83.2%76.0% 84.6% 2.2% #3 (SK3) Aqua #1 83.0% 77.9% 85.7% 79.5% 87.2% 2.2%(AQ1) Aqua #1 83.0% 77.9% 85.7% 79.5% 87.2% 2.2% (AQ1) Aqua #2 79.7%75.9% 82.0% 76.8% 83.7% 2.3% (AQ2) Aqua #3 77.3% 69.9% 81.1% 72.2% 83.5%2.1% (AQ3)

In one exemplary embodiment, trial lens kit 100 includes an Ultraviolet(UV) trial lens or UV blocker which is operable to filter or block UVlight. The UV trial lens may be made using a dye well known in theoptics industry.

One or more trial lenses of trial lens kit 100 may be used or combinedtogether to achieve improved visual function. For example, each triallens, alone or in combination with other lenses, may uniquely expand thefield of view, enhance perception, neurovisual processing, and decreasereaction time.

Such improved visual function may manifest as an improvement of apupillary anomaly. The effect (e.g., benefits) of a particular triallens on pupillary anomalies can be viewed by a doctor using a cameraduring testing with the various lenses of trial lens kit. For example,the doctor can watch the pupillary responses, sizing, and shaping of thepupil to normal size. It is appreciated that there may be geneticpredispositions to pupillary anomalies and aliments which correlate toneurovisual responses that may be treated with one or more trial lenses.

Embodiments of the present invention are operable for use in improving avariety of various visual performance and visual functioncharacteristics including improved visual acuity (e.g., more clear andenhanced visual perception of distant objects), improved visual field,enhanced visual saccade (e.g., eye movement across a page), increasedcontrast sensitivity, and increased recognition of color hues.Embodiments of the present invention are further operable to improvevisual performance and visual function characteristics includingincreased eye coordination, increased pupil stabilization (e.g.,stabilization of pupil shape to round), improved visual invoked responsetime (e.g., vision to action time), and improved blood flow in the brainwhich results in enhancement to cognitive response to visual cues. Thefollowing terms may be trademarked or protected: neurochromatic andneurochromatic refraction.

In one embodiment, the improvement in visual performance and function issubstantially similar to the improvements in visual performance andfunction that ophthalmologists and optometrists look for. Embodiments ofthe present invention are operable for determination of a neurochromaticprescription resulting in neurological and physiological improvement.Embodiments of the present invention comprise a plurality of triallenses, each corresponding to frequencies or wavelengths to be used incombination to create a prescription which can be used to create aresultant lens to increase visual function (e.g., visual performance andvisual function characteristics mentioned above).

Each lens of trial lens kit 100 may correspond to a particularwavelength or frequency of light that is filtered and thus have aparticular tinting or density. Each trial lens may be tinted orotherwise configured to filter light based on particular wavelength orfrequency. Each trial lens may be created by a dyeing process which mayuse a single dye or a mixture of dyes to make a unique trial lens. It isappreciated that glass or plastic may be used as long as the differentrefraction properties of glass and plastic are taken into account. Inone embodiment, the tinting is done by time, heat, and saturation of thelens.

Each trial lens may thus correspond to particular pupillary responserelated to a specific pathology, anomaly, or syndrome. For example,visual field is impacted by the wavelength of the trial lens whichimpacts the measurable clarity of vision. A trial lens may furtheraffect the ability of the eyes to function together which allowsconvergence and divergence in the behavior of the eyes to be observed.

Trial lens kit 100, as described herein, is operable for use indetermining a neurochromatic prescription to enhance visual performanceand/or provide neurovisual therapeutic intervention therapy for thesymptoms, syndromes, conditions, and anomalies exemplified within TableII. Each wavelength or frequency may be selected to address pupillaryanomalies and/or address the aliments of Table II. It is appreciatedthat neurochromatic lenses may provide enhanced visual performanceand/or therapy for other symptoms, syndromes, conditions, and anomaliesas well.

TABLE II Exemplary symptoms, syndromes, conditions, and anomalies whichneurochromatic lens provide relief 1 Visual and auditory dyslexia. 2Blurred vision not fully corrected by ophthalmic lenses. 3 Contrastsensitivity compromises. 4 Color vision recognition compromises. 5Restricted or compromised neurovisual fields of vision. 6 Convergenceand divergence insufficiency. 7 Unilateral diplopia. 8 Compromises ofnight vision. 9 Wet and dry macular degeneration. 10 Visual aberrationsand delusions not related to a psychotic or delusional condition. 11Photophobia. 12 Visually evoked migraines. 13 Migraines characterized byaurora, photosensitivity, aberrations, dizziness, limited vision, orblindness. 14 Post migraines characterized by any one of the above. 15Visually evoked seizure phenomena characterized by light stimulation orby any one of the above. 16 Post seizure activity characterized by anyone of the above. 17 Cranial and brain hemorrhages. 18 Compromises ofvisual performance and cognitive awareness/alertness caused by bloodblockage or hemorrhages (e.g., stroke) and/or traumatic brain injuriesor post surgical trauma. 19 Some forms of schizophrenia or schizoidphenomena including delusional auditory and visually inducedhallucination-type activities. 20 Reduction in autistic-type overstimulation of the visual and auditory kind. 21 Compromised saccadeperformance. 22 Irregular and inconsistent pupillary responses to lightand focus activities. 23 Compromised cognitive performance not relatedto conditioned responses of learning or physical development. 24 Eyepain and strain related to visual performance. 25 Headaches related tovisual pain or strain. 26 Neck and shoulder pain or distress related tovisual stress. 27 Compromised reading speeds related to visualperformance. 28 Compromised recall related to visual or auditorystimulation. 29 Non-migraine visually induced headaches, stress, ordiscomfort. 30 Seasonal affective disorder. 31 Computer vision syndrome.32 Compromises in depth recognition and perception. For example, somepatients cannot sustain a sight vocabulary or recognition of othervisual data which appears to be a problem of either cognition, memory,or concentration of the neurovisual data that was heretofore alreadycompromised. 33 Body coordination and physical performance requiringvisual stimulation as one of several variables of perception. 34Disorientation to space and motion. 35 Motion sickness. 36 Fear ofheights. 37 Claustrophobia-type responses that cause a constriction andexpansion of pupils seemingly consciously uncontrollable. 38 Some formsof general and specific anxiety disorders. 39 Physiologically relatedartistic performance. 40 Amblyopic (a.k.a. lazy eye) or wandering eye.41 Excessive eye dominance. 42 Suppressive vision or visual performanceof one eye not related to eye trauma, disease, or aging. 43 Specificphotophobia related to lighting conditions, working environments, tasks,seasons of the year, or tools. 44 Post surgical photophobia. 45 Posttraumatic brain injuries independent of hemorrhages or not. 46 Posttraumatic stress disorders or syndromes. 47 Post concussion hyper-lightsensitivity. 48 Compromised night vision. 49 Hyper-sensitive night orstorm-type related vision compromises. 50 Myopia phenomena. 51Astigmatism phenomena. 52 Strabismus phenomena. 53 “Comfort” or“performance” (e.g., +0.25 to +0.50) ophthalmic prescriptions. 54Pharmaceutical prescription induced photophobia, e.g., caused by mosthormonal based medications such as birth control or menopausalprescriptions. 55 Compromises in spatial differentiation. 56 Disparitybetween reading, writing, or mathematic capabilities as to any or all ofthese related to kinesthetic and/or mechanical aptitude. 57 Visualcomprehension enhanced by “hearing the words” inside one's head or byreading out-loud to process fully. 58 The use of a finger or any otherkind of marker or place keeper to read and maintain proper tracking. 59High end near-sighted prescriptions. 60 Patients suffering from minor tosevere depression (e.g., situational to needs of chronic dimness orbrightness of light). 61 Lacking in physical coordination or clumsiness.62 Premature fatigue or sleepiness with prolonged visual tasks includingand not limited to driving, reading, sewing, sightseeing. 63 Nausea orupset stomach with visual tasks. 64 Abnormal pupillary sizes and shapesnot related to bright or darkness. 65 Patients who experience “glare” orexcessive brightness in normal lighting conditions and situations. 66Patients who cannot drive at night or in stormy conditions because offailed or compromised vision. 67 Patients who report a “smudged” or“fogged” vision where upon a physiological examination there are noknown causal factors. 68 Patients who report visual aberrations such asletters or words moving, switching, disappearing, fading away, changingsize or shape, having a glow or luminance around print or coming fromthe background of the print. These and other dyslexic symptoms are knownto respond to a neurochromatic lens. 69 Patients who see a whitebackground on the printed page, from art, as having a color or hue, orglare. 70 Patients who see night lighting such as street lights, vehiclelights as having a color or hue, streaks, or having an abnormal comfortor affect. 71 Patients affected by chronic and severe fevers. 72Patients affected by Down Syndrome. 73 Patients with compromises incognitive function caused by disease, accident, or trauma. 74 Patientswith varied degenerative muscular diseases. 75 Patients affected withchronic fatigue syndrome. 76 Limited or narrow band of light spectrumphotophobia. 77 Major depression not identified as seasonal affectivedisorder. 78 Post traumatic stress disorder visually evoked symptoms. 79Patients who complain or say there is excessive glare or aberrationsabound the words and images of printed material. 80 Patients whocomplain or say there never is enough light to read comfortably oreffectively. 81 Patients identified as having retinal pigmatosa, Graves'disease, chromic fatigue syndrome, degenerative muscle diseases ofvaried sorts, connective tissue diseases of varied sorts, lupuspatients, other auto-immune diseased or compromised patients, patientshaving chemo or radiation therapies. 82 Patients with albinoism. 83Compromised visually evoked responses. 84 Situational visual compromiseor visual difficulties.

FIG. 2 shows a block diagram of an exemplary trial lens in accordancewith an embodiment of the present invention. FIG. 2 depicts exemplarytrial lens 200 including viewing area 202 and label area 210. In oneexemplary embodiment, one side of trial lens 200 has a scratch resistantcoating.

Label area 210 facilitates handling of exemplary trial lens 200 suchthat viewing area 202 is not touched or collects fingerprints. In oneembodiment, label area 210 includes trial lens identifier 212 whichindicates the lens group (e.g., color or type of lens) and number of thetrial lens in the group of lenses (e.g., the respective color in thecolor lens group). For example, trial lens identifier 212 may indicatethat exemplary trial lens 200 is the third blue lens of the trial lenskit (e.g., Blue #3 or BL3 lens) which corresponds to a specificwavelength or frequency. Trial lens identifier 212 may be laser engravedin exemplary trail lens 200 and may further include a tradename ortrademark (e.g., NCV-Rx).

Viewable portion 202 is the portion of exemplary trial lens 200 that hasbeen modified to filter out a specific wavelength or frequency of light.In one embodiment, viewable portion 202 comprises areas 220 which arethe areas that a patient looks through during the determination ofchromatic prescription. The chromatic prescription may be determined asdescribed in copending non-provisional patent application Ser. No.13/368,149, Attorney Docket Number NCVS-0001.US1, entitled“NEUROCHROMATIC PRESCRIPTION DETERMINATION,” with filing date Feb. 7,2012, and hereby incorporated by reference in its entirety. Thedetermination of the prescription may be determined using a refractiondevice as described in copending non-provisional patent application Ser.No. ______, Attorney Docket Number NCVS-0001.US3, entitled“NEUROCHROMATIC REFRACTOR,” with filing date ______, and herebyincorporated by reference in its entirety.

In one embodiment, an exemplary trial lens 200 is 140 mm in length, 50mm in height, and 2.5 mm in thickness or width. The thickness ofexemplary trial lens may correspond to a 99.8% light transmission.Exemplary trial lens 200 may be of a thickness to allow or facilitatedetermination of a chromatic (e.g., neurochromatic prescription)prescription that allows neurochromatic lenses to be created therefrom(e.g., via a dying process as described herein). In one exemplaryembodiment, trial lens 200 may be made out of plano optical qualitytintable plastic.

In one embodiment, trial lens 200 is designed to substantially matchophthalmic standard and in particular allows use of the lens while lightcomes in from behind the patient looking though trial lens 200.

FIG. 3 shows a block diagram of an exemplary case in accordance with anembodiment of the present invention. Exemplary case 300 comprises topportion 310, trial lens holder 306, and bottom portion 302. Exemplarycase 300 is operable to facilitate transportation of a trial lens kit(e.g., trial lens kit 100) and optional refractor device (e.g.,refractor device 304).

In one embodiment, exemplary case 300 comprises two layers: a firstlayer for holding or storing refractor device 304 in bottom portion 302and a second layer for holding or storing trial lenses 308 (e.g., triallens kit 100) in trial lens holder 306. Trial lens holder 306 may beremoved (e.g., lifted out) from exemplary case 300 to allow for accessto refractor device 304. Trial lens holder 306 may be made of wood,foam, or any material capable of supporting trial lenses 308 duringtransportation without causing damage to trial lenses 308. In anotherembodiment, exemplary case 300 is a reversible case that allows removalof refractor device 304 from one side of the case and removal of triallenses 308 from the other side of the case. Exemplary case 300 may beconfigured to have hinges and operate in a similar manner to a briefcase (e.g., with a handle and mechanisms to facilitate closing thecase). Exemplary case 300 may be made with a variety of metals includingstainless steel, aluminum, high impact plastic, or other materials. Inone embodiment, exemplary case 300 may be 16 inches long and 14 incheswide and have ½ inch spacing between trial lenses.

Refractor 304 may be folded up for storage in bottom portion 302.Refraction device 304 may be a neurochromatic refractor device asdescribed in related copending non-provisional patent application Ser.No. ______, Attorney Docket Number NCVS-0001.US3, entitled“NEUROCHROMATIC REFRACTOR,” with filing date ______. Refractor device304 and trial lenses 308 facilitate determination of a chromaticprescription.

In one embodiment, the overall performance of photoreceptor cells at theretinal level is improved thereby changing the electrical signals goingto the brain and changing blood flow. Embodiments of the presentinvention are operable to change the blood flow in the brain therebyresulting in measurable improvements in visual performance. Embodimentsof the present invention are operable to adjust light received by theeyes which can result in beneficial changes in hormone response (e.g.,seasonal effective disorder).

Embodiments of the present invention further facilitate increased visualacuity (e.g., more clear, bold, or distinct), increased visual field,enhanced visual saccade, increase contrast and sensitivity, increasedrecognition of visual color/hues, and increased blood flow resulting inenhanced cognitive response to visual queues. Embodiments of the presentinvention are operable determination of a resultant lens for increasedutility of both eyes working coordinately (e.g., vortex of function andfocus). For example, the eyes may not be seeing the same point resultingin some degree of reversal or dyslexia. This may create a perceptionthat things are moving or going in and out of focus. The improvementsfacilitated by embodiments of the present invention can be measured withmachines which determine where the pupils of both eyes are actuallyaiming.

Embodiments of the present invention are further operable to facilitatestabilization of the pupillary response to visual stimulation. Forexample, patients may have observable difficulty reading or duringexposure to certain light which manifests as an abnormal shape or notround pupil. The abnormal shape of the pupil may cause the patient toexperience eye fatigue, eye strain, and loss of place (e.g., whilereading). Embodiments of the present invention can stabilize thepupillary response to result in a round pupil thereby enhancing othermechanical and neurophysical aspects of vision.

Embodiments of the present invention additionally facilitate enhancedvisually evoked response time. For example, the time to blink whensomething comes toward your eye or time to shoot a weapon when somethingcomes into your visual field may be lessened. In other words,embodiments of the present invention are operable to enhanced visualresponse time. Each of these improvements may be monitored during thetrial lens (e.g., neurochromatic trial lens) selection process.

It is noted that some native populations have little trouble withnear-sightedness or far-sightedness, stigmatism, etc. until they startto read because of how their eyes have been adapted over centuries. Theproblems may develop as a result of prolonged focused vision.Embodiments of the present invention are operable to provide treatmentfor problems that develop as a result of prolonged focused vision.

The foregoing descriptions of specific embodiments of the presentinvention have been presented for purposes of illustration anddescription. They are not intended to be exhaustive or to limit theinvention to the precise forms disclosed, and many modifications andvariations are possible in light of the above teaching. The embodimentswere chosen and described in order to best explain the principles of theinvention and its practical application, to thereby enable othersskilled in the art to best utilize the invention and various embodimentswith various modifications as are suited to the particular usecontemplated. It is intended that the scope of the invention be definedby the claims appended hereto and their equivalents.

1. A trial lens kit comprising: a first plurality of trial lenseswherein each of said first plurality of trial lenses is operable tofilter a particular wavelength of light, and wherein said firstplurality of trial lenses corresponds to a first type of visual functionimprovement; and a second plurality of trial lenses wherein each of saidsecond plurality of trial lenses is operable to filter a particularwavelength of light, and wherein said second plurality of trial lensescorresponds to a second type of visual function improvement.
 2. Thetrial lens kit of claim 1 wherein individual lenses of said firstplurality of trial lenses and individual lenses of said second pluralityof trial lenses are operable to be combined for determining a chromaticprescription.
 3. The trial lens kit of claim 1 wherein said first typeof visual function improvement and said second type of visual functionimprovement are related to a first pupillary anomaly and a secondpupillary anomaly respectively.
 4. The trial lens kit of claim 1 whereinsaid first plurality of trial lenses comprises colored trial lenses. 5.The trial lens kit of claim 4 wherein said colored trial lenses are madeof tinted plastic.
 6. The trial lens kit of claim 1 wherein said secondplurality of lenses comprises infrared (IR) trial lenses operable tofilter IR wavelengths.
 7. The trial lens kit of claim 1 furthercomprising: a third plurality of trial lenses wherein each of said thirdplurality of trial lenses is operable to filter ultraviolet (UV) light,and wherein said third plurality of trial lenses corresponds to a thirdtype of visual function improvement.
 8. An apparatus for determinationof a chromatic prescription, said apparatus comprising: a first triallens operable to filter a first portion of the electromagnetic spectrumand corresponding to a first type of visual function improvement relatedto a first pupillary anomaly; and a second trial lens operable to filtera second portion of the electromagnetic spectrum and corresponding to asecond type of visual function improvement related to a second pupillaryanomaly, wherein said first trial lens and said second trial lens areoperable to be combined to correspond to a third visual functionimprovement.
 9. The apparatus as described in claim 8 wherein said firsttrial lens corresponds to a first tint of a color and said second triallens corresponds to a second tint of said color.
 10. The apparatus asdescribed in claim 9 wherein said first trial lens and said second triallens are tinted via a dyeing process.
 11. The apparatus as described inclaim 9 wherein said color is selected from the group consisting of red,orange, yellow, green, blue, indigo, and violet.
 12. The apparatus asdescribed in claim 8 wherein said first trial lens corresponds to afirst ultraviolet (UV) wavelength and said second trial lens correspondsto a second ultraviolet wavelength.
 13. The apparatus as described inclaim 8 wherein said first trial lens corresponds to a first infrared(IR) wavelength and said second trial lens corresponds to a secondinfrared wavelength.
 14. The apparatus as described in claim 8 whereinsaid first trial lens and second trial lens are made of plastic and madesubstantially accordingly to ophthalmic standards.
 15. A lens kitcomprising: a plurality of color trial lenses corresponding to a firstvisual function improvement; a plurality of ultraviolet (UV) triallenses corresponding to a second visual function improvement; and aplurality of infrared (IR) trial lenses corresponding to a third visualfunction improvement, wherein individual lenses of said plurality ofcolor trial lenses, individual lenses of said plurality of UV triallenses, and individual lenses of said plurality of IR trial lenses areoperable in combination for determination of a chromatic prescription.16. The lens kit of claim 15 further comprising: a plurality of neutraldensity trial lenses corresponding to a fourth visual functionimprovement.
 17. The lens kit of claim 15 further comprising: aplurality of plated lenses corresponding to a fifth visual functionimprovement.
 18. The lens kit of claim 15 wherein said first visualfunction improvement and said second visual function improvement arerelated to a first pupillary anomaly and a second pupillary anomalyrespectively.
 19. The lens kit of claim 15 wherein said plurality ofcolor trial lenses is made of tinted plastic.
 20. The lens kit of claim19 wherein said plurality of color trial lenses is tinted using a dyeingprocess.